Login to Your Account

Novavax, VaxInnate Get Welcome Shot in the Arm

By Mari Serebrov

Wednesday, March 2, 2011
WASHINGTON – Two government contracts that could be worth up to nearly $200 million each will inoculate Novavax Inc. and VaxInnate Inc. against some of the financial risks involved in getting their recombinant influenza vaccines through clinical development.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription